13 January 2023

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

NOTICE OF 2022 ANNUAL GENERAL MEETING

Allergy Therapeutics plc has today published it's Notice of 2022 Annual General Meeting.   It is available electronically on the Company's website at www.allergytherapeutics.com

A hard copy of the Notice of Meeting has been posted to shareholders on 13 January 2023.

- ENDS -

For further information, please contact:

Allergy Therapeutics

+44 (0)1903 845 820

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

Panmure Gordon (Nominated Adviser and Broker)

+44 (0)20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

[email protected]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved 10% compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.